MX2021012960A - Composiciones y metodos de uso de cannabinoides para neuroproteccion. - Google Patents

Composiciones y metodos de uso de cannabinoides para neuroproteccion.

Info

Publication number
MX2021012960A
MX2021012960A MX2021012960A MX2021012960A MX2021012960A MX 2021012960 A MX2021012960 A MX 2021012960A MX 2021012960 A MX2021012960 A MX 2021012960A MX 2021012960 A MX2021012960 A MX 2021012960A MX 2021012960 A MX2021012960 A MX 2021012960A
Authority
MX
Mexico
Prior art keywords
neuroprotection
compositions
methods
cannabinoids
neuroprotective composition
Prior art date
Application number
MX2021012960A
Other languages
English (en)
Inventor
Eric Hsu
Ujendra Kumar
Rishi Kumar Somvanshi
Shenglong Zou
Original Assignee
Inmed Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inmed Pharmaceuticals Inc filed Critical Inmed Pharmaceuticals Inc
Publication of MX2021012960A publication Critical patent/MX2021012960A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

En la presente se proporcionan métodos y composiciones para la neuroprotección. La composición neuroprotectora puede ser o incluir cannabinol o un derivado de este. La composición neuroprotectora se puede utilizar en el tratamiento de una enfermedad neurodegenerativa. La composición neuroprotectora se puede usar para proteger las neuronas retinianas de la degeneración en un sujeto que lo necesite, tal como para el tratamiento del glaucoma.
MX2021012960A 2019-04-24 2020-04-24 Composiciones y metodos de uso de cannabinoides para neuroproteccion. MX2021012960A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962838216P 2019-04-24 2019-04-24
PCT/CA2020/050547 WO2020215164A1 (en) 2019-04-24 2020-04-24 Compositions and methods for use of cannabinoids for neuroprotection

Publications (1)

Publication Number Publication Date
MX2021012960A true MX2021012960A (es) 2022-01-04

Family

ID=72940570

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021012960A MX2021012960A (es) 2019-04-24 2020-04-24 Composiciones y metodos de uso de cannabinoides para neuroproteccion.

Country Status (11)

Country Link
US (1) US20230043428A1 (es)
EP (1) EP3958856A4 (es)
JP (1) JP2022530471A (es)
KR (1) KR20220080045A (es)
CN (1) CN114007603A (es)
AU (1) AU2020261515A1 (es)
CA (1) CA3134764A1 (es)
IL (1) IL287536A (es)
MX (1) MX2021012960A (es)
SG (1) SG11202111809XA (es)
WO (1) WO2020215164A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115006404A (zh) * 2022-08-09 2022-09-06 昆药集团股份有限公司 一种具有视神经保护功效的药物组合物及其应用
US20240139272A1 (en) * 2022-10-27 2024-05-02 Kemin Industries, Inc. Use of a spearmint extract for retina neurotrophism

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018071452A1 (en) * 2016-10-11 2018-04-19 Growblox Life Sciences L.L.C. Cannabinoid-containing complex mixtures for the treatment of neurodegenerative diseases
KR20200019864A (ko) * 2017-05-08 2020-02-25 인메드 파마슈티컬스 인코포레이티드 안구용 약물 전달 제형
WO2018205038A1 (en) * 2017-05-12 2018-11-15 Tetra Bio-Pharma Inc. Compositions comprising cannabinoids and terpenes useful in the treatment of cancer and vascular ocular disorders via inhibition of hedgehog signalling

Also Published As

Publication number Publication date
JP2022530471A (ja) 2022-06-29
WO2020215164A1 (en) 2020-10-29
EP3958856A4 (en) 2023-01-25
CN114007603A (zh) 2022-02-01
CA3134764A1 (en) 2020-10-29
IL287536A (en) 2021-12-01
US20230043428A1 (en) 2023-02-09
KR20220080045A (ko) 2022-06-14
SG11202111809XA (en) 2021-11-29
EP3958856A1 (en) 2022-03-02
AU2020261515A1 (en) 2021-11-18

Similar Documents

Publication Publication Date Title
WO2018115097A9 (en) Ophthalmic composition for treatment of dry eye disease
PH12015501942A1 (en) Susbtituted 3-phenylpropylamine derivatives for the treatment of opthalmic diseases and disorders
MX2016014634A (es) Compuestos para el tratamiento de enfermedades y trastornos oftalmicos.
PH12015501207A1 (en) Amine derivative compounds for treating ophthalmic diseases and disorders
WO2017070647A8 (en) Nicotinamide for use in the treatment and prevention of ocular neurodegenerative disorder (e.g. glaucoma)
WO2007076360A8 (en) (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)- pyrazines for treating rho kinase-mediated diseases and conditions
WO2007046083A3 (en) Compositions for treatment of eye diseases
WO2017218981A3 (en) Compositions and methods for reducing ocular neovascularization
WO2010028088A3 (en) Sulfur-linked compounds for treating opthalmic diseases and disorders
WO2019030762A3 (en) CANNABIS AND ITS DERIVATIVES FOR THE TREATMENT OF PAIN RELATED TO PAIN AND BONE REGENERATION ASSOCIATED WITH BONE DEFECTS IN THE JAW
MX2021012960A (es) Composiciones y metodos de uso de cannabinoides para neuroproteccion.
EP3492096A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF EYE DISEASES WITH CAS9 PROTEINS AND GUIDE RNA
CR20220216A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
EP4272832A3 (en) Antimicrobial compounds, compositions, and uses thereof
EP3934646A4 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF OCULAR DISEASES OR DISORDERS
WO2015048188A8 (en) Modified fibroblast growth factors for the treatment of ocular disorders
EP3618868A4 (en) METHODS AND COMPOSITIONS FOR TREATING ALLERGIC EYE DISEASES
WO2013189606A3 (en) Interval therapy for the treatment of loss of eyesight in humans with glaucoma and other degenerative eye diseases
CR20210544A (es) DERIVADOS DE 1,1-DIÓXIDO DE 3-AMINO-4H-BENZO[E][1,2,4] tiadiazina COMO INHIBIDORES DE MRGX2
MX2021006070A (es) Formulaciones oculares para la administracion de farmacos y proteccion del segmento anterior del ojo.
EP3691654A4 (en) OPHTHALMIC PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATMENT OF EYE SURFACE DISEASES
AU2018260628A1 (en) Pharmaceutical composition comprising tryptophan and phyllokinin derivative for use in treating psychiatric and psychological conditions
MX2019007041A (es) Metodos y composiciones para tratar la enfermedad de parkinson.
MX2020012012A (es) Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular.
CL2020001426A1 (es) Composición tópica oftálmica que comprende ácido dobesilico para tratar enfermedades del segmento posterior del ojo.